[go: up one dir, main page]

MX347429B - Cristales de múltiples componentes que comprenden dasatinib y formadores de cocristales seleccionados. - Google Patents

Cristales de múltiples componentes que comprenden dasatinib y formadores de cocristales seleccionados.

Info

Publication number
MX347429B
MX347429B MX2014015433A MX2014015433A MX347429B MX 347429 B MX347429 B MX 347429B MX 2014015433 A MX2014015433 A MX 2014015433A MX 2014015433 A MX2014015433 A MX 2014015433A MX 347429 B MX347429 B MX 347429B
Authority
MX
Mexico
Prior art keywords
dasatinib
cocrystal formers
multicomponent crystals
multicomponent
gallate
Prior art date
Application number
MX2014015433A
Other languages
English (en)
Other versions
MX2014015433A (es
Inventor
Szelagiewicz Martin
Blatter Fritz
Chiodo Tiziana
Hafner Andreas
Hintermann Tobias
Salvador Beate
Siebenhaar Bernd
Vossen Marcus
Original Assignee
Basf Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Se filed Critical Basf Se
Publication of MX2014015433A publication Critical patent/MX2014015433A/es
Publication of MX347429B publication Critical patent/MX347429B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic
    • C07C35/08—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a six-membered rings
    • C07C35/12—Menthol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C07C47/58—Vanillin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a un sistema cristalino de componentes múltiples (co-cristal) que comprende un compuesto de la fórmula I (INN: Dasatinib) y un segundo compuesto seleccionado de metil-4-hidroxibenzoato, o nicotinamida, o galato de etilo, o galato de metilo, o galato de propilo, o etil maltol o vainillina, o mentol, o (1R,2S,5R)-(-), así como a un proceso para obtenerlo.
MX2014015433A 2012-06-15 2013-06-13 Cristales de múltiples componentes que comprenden dasatinib y formadores de cocristales seleccionados. MX347429B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261659997P 2012-06-15 2012-06-15
EP12172172 2012-06-15
PCT/IB2013/054832 WO2013186726A2 (en) 2012-06-15 2013-06-13 Multicomponent crystals comprising dasatinib and selected cocrystal formers

Publications (2)

Publication Number Publication Date
MX2014015433A MX2014015433A (es) 2015-09-16
MX347429B true MX347429B (es) 2017-04-26

Family

ID=49758817

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015433A MX347429B (es) 2012-06-15 2013-06-13 Cristales de múltiples componentes que comprenden dasatinib y formadores de cocristales seleccionados.

Country Status (12)

Country Link
US (1) US9340536B2 (es)
EP (1) EP2861589B1 (es)
JP (1) JP6211072B2 (es)
KR (1) KR20150020683A (es)
CN (1) CN104379582A (es)
AU (1) AU2013276138B2 (es)
BR (1) BR112014031292A2 (es)
CA (1) CA2876539A1 (es)
ES (1) ES2637829T3 (es)
MX (1) MX347429B (es)
RU (1) RU2650524C2 (es)
WO (1) WO2013186726A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX347429B (es) 2012-06-15 2017-04-26 Basf Se Cristales de múltiples componentes que comprenden dasatinib y formadores de cocristales seleccionados.
WO2013189910A1 (en) 2012-06-22 2013-12-27 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
CA2879792A1 (en) 2012-08-06 2014-02-13 Basf Se Multicomponent crystalline system comprising deferasirox and isonicotinamide and a process for the preparation thereof
RU2652121C2 (ru) 2012-10-19 2018-04-25 Басф Се Многокомпонентная кристаллическая система, содержащая нилотиниб и выбранные сокристаллообразователи
CA2917209A1 (en) 2013-07-25 2015-01-29 Basf Se Salts of dasatinib in amorphous form
CN105408329A (zh) 2013-07-25 2016-03-16 巴斯夫欧洲公司 呈晶体形式的达沙替尼的盐
US20180230140A1 (en) 2014-06-30 2018-08-16 Basf Se Multicomponent crystals of dasatinib with menthol or vanillin
IT201700006157A1 (it) * 2017-01-20 2018-07-20 Cerbios Pharma Sa Co-cristalli di un composto antitumorale
IT201700006145A1 (it) * 2017-01-20 2018-07-20 Cerbios Pharma Sa Co-cristallo di un composto antitumorale
CN111108104A (zh) * 2017-07-07 2020-05-05 拜康有限公司 达沙替尼的多晶形式
JP7166754B2 (ja) * 2017-11-22 2022-11-08 沢井製薬株式会社 ダサチニブ無水物含有製剤
WO2019209908A1 (en) 2018-04-25 2019-10-31 Johnson Matthey Public Limited Company Crystalline forms of dasatinib
CA3102381A1 (en) 2018-06-15 2019-12-19 Handa Oncology, Llc Kinase inhibitor salts and compositions thereof
US10799459B1 (en) 2019-05-17 2020-10-13 Xspray Microparticles Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
CN112028896A (zh) * 2020-10-14 2020-12-04 奥锐特药业(天津)有限公司 阿卡替尼的新晶型及其制备方法
CN114805046B (zh) * 2022-04-25 2023-05-12 东华理工大学 香草醛与酰胺类化合物的共晶结构及其制备方法
WO2024218275A1 (en) * 2023-04-20 2024-10-24 Institut Gustave Roussy Liquid and solid compositions of imipridone derivatives

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144910A0 (en) 1999-04-15 2002-06-30 Bristol Myers Squibb Co Cyclic compounds and pharmaceutical compositions containing the same
WO2004078163A2 (en) * 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TWI338004B (en) * 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
PT1786799E (pt) * 2004-09-09 2012-09-18 Natco Pharma Ltd Novos derivados de fenilaminopirimidina como inibidores de bcr-abl cinase
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
CN101287725A (zh) * 2005-04-15 2008-10-15 库多斯药物有限公司 Dna-pk抑制剂
EP1937270A1 (en) 2005-09-21 2008-07-02 Brystol-Myers Squibb Company Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
AU2006315718B2 (en) * 2005-11-10 2012-10-04 Merck Sharp & Dohme Corp. Imidazopyrazines as protein kinase inhibitors
JP2009515992A (ja) * 2005-11-16 2009-04-16 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用なアミノピリミジン
CN101679362A (zh) * 2006-12-20 2010-03-24 拜尔保健公司 用于治疗癌症的 4 -{ 4 - [ ({ 3 -叔丁基 - 1 - [ 3 - (羟基甲基 )苯基 ] - 1 h -吡唑 - 5 -基} -氨基甲酰基)-氨基]-3-氟苯氧基}-n-甲基吡啶-2-甲酰氨及其前药和盐
EP2537847A1 (en) 2007-10-23 2012-12-26 Teva Pharmaceutical Industries, Ltd. Polymorphs of dasatinib and process for preparation thereof
CN102112478A (zh) * 2008-06-10 2011-06-29 普莱希科公司 用于激酶调节的5h-吡咯[2，3-b]吡嗪衍生物和其适应症
WO2010062715A2 (en) * 2008-11-03 2010-06-03 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
WO2010067374A2 (en) 2008-12-08 2010-06-17 Hetero Research Foundation Polymorphs of dasatinib
CZ20098A3 (cs) * 2009-01-13 2010-07-21 Zentiva, K.S. Lékové formy inhibitoru tyrosinových kináz
AU2010230344B9 (en) * 2009-03-30 2014-11-27 Janssen Sciences Ireland Uc Co-crystal of etravirine and nicotinamide
CN102770434A (zh) * 2009-12-03 2012-11-07 阿斯利康(瑞典)有限公司 三唑并[4,5-d]嘧啶血小板聚集抑制剂的共晶体
CA2806820A1 (en) * 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited N-methylformamide solvate of dasatinib
US9249108B2 (en) 2010-11-22 2016-02-02 Basf Se Multicomponent system of rosuvastatin calcium salt and sorbitol
CN102030745B (zh) 2010-11-26 2012-05-09 江苏先声药物研究有限公司 Dasatinib溶剂合物及其制备方法
WO2012143308A1 (en) 2011-04-18 2012-10-26 Basf Se Multicomponent crystalline system of rosuvastatin calcium salt and vanillin
CA2841655A1 (en) 2011-07-26 2013-01-31 Basf Se Multicomponent crystalline system of ezetimibe and proline
CA2858316A1 (en) 2011-12-06 2013-06-13 Basf Se Multicomponent crystalline system of voriconazole with fumaric acid
US8796481B2 (en) 2011-12-30 2014-08-05 Basf Se Crystalline solvate and non-solvated forms of 6,6′-[[3,3′,5,5′-tetrakis(1,1-dimethylethyl)-[1,1′biphenyl]-2,2′-diyl]bis(oxy)]bis-dibenzo [d,f] [1,3,2]-dioxaphosphepine
CN104144935B (zh) 2011-12-30 2016-07-06 巴斯夫欧洲公司 6，6’-[[3，3’，5，5’-四(1，1-二甲基乙基)-[1，1’-联苯]-2，2’-二基]双(氧基)]双-二苯并[d，f][1，3，2]-二氧杂磷杂庚因的结晶溶剂化物和非溶剂化形式
AU2013242103A1 (en) 2012-03-29 2014-10-16 Basf Se Co-crystals of dicamba and a co-crystal former B
CA2871315C (en) 2012-05-25 2020-11-03 Basf Se Crystalline form a of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2h-benzo[b][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione
BR112014028872A2 (pt) 2012-05-25 2017-06-27 Basf Se forma b cristalina, processo para a produção das formas b e ab, mistura da forma b cristalina, agente de proteção, uso da forma b cristalina e método para o combate do crescimento indesejado dos vegetais
MX347429B (es) 2012-06-15 2017-04-26 Basf Se Cristales de múltiples componentes que comprenden dasatinib y formadores de cocristales seleccionados.

Also Published As

Publication number Publication date
CA2876539A1 (en) 2013-12-19
WO2013186726A2 (en) 2013-12-19
AU2013276138A1 (en) 2015-01-22
US9340536B2 (en) 2016-05-17
KR20150020683A (ko) 2015-02-26
AU2013276138B2 (en) 2017-02-23
ES2637829T3 (es) 2017-10-17
EP2861589A4 (en) 2016-03-02
JP2015525227A (ja) 2015-09-03
EP2861589A2 (en) 2015-04-22
EP2861589B1 (en) 2017-05-17
JP6211072B2 (ja) 2017-10-11
RU2015100280A (ru) 2016-08-10
RU2650524C2 (ru) 2018-04-16
BR112014031292A2 (pt) 2017-06-27
WO2013186726A3 (en) 2014-02-20
CN104379582A (zh) 2015-02-25
US20150133463A1 (en) 2015-05-14
MX2014015433A (es) 2015-09-16

Similar Documents

Publication Publication Date Title
MX347429B (es) Cristales de múltiples componentes que comprenden dasatinib y formadores de cocristales seleccionados.
CY1123670T1 (el) Κρυσταλλικο παραγωγο 6,7-ακορεστης-7-καρβαμοϋλ μορφινανης, και μεθοδος για την παραγωγη αυτου
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
EA201500173A1 (ru) Фунгицидные композиции
WO2013091775A3 (de) Verwendung von cyclohexanolderivaten als antimikrobielle wirkstoffe
CA2830549C (en) Methods and compositions for preparing noribogaine from voacangine
WO2015008218A3 (en) Process for the preparation of suvorexant and intermediates useful in the synthesis of suvorexant
WO2013093931A3 (en) Novel prodrugs of phenolic drugs
FR2916435B1 (fr) Nouveau procede de preparation de la zolithe eu-1.
FR2984333B1 (fr) Procede de preparation d'un melange-maitre en phase liquide.
FR2975990B1 (fr) Procede de preparation d'un compose organique fluore
WO2014159794A3 (en) Bicyclo [2.2.1] acid gpr120 modulators
WO2014017938A3 (en) Process for the synthesis of substituted urea compounds
WO2012131707A3 (en) Crystalline form of bortezomib, preparation method and pharmaceutical composition there f
WO2014207567A3 (en) Process for the preparation of abiraterone and intermediates thereof
TN2013000354A1 (en) Synthesis of 2-carboxamide cycloamino urea derivatives
NZ627473A (en) Aryloxyacetamide compound and pesticide
CY1114704T1 (el) Κρυσταλλικη μορφη δ του αλατος αργινινης της περινδοπριλης, μεθοδος παρασκευης της και φαρμακευτικες συνθεσεις οι οποιες την περιεχουν
IN2014MN00971A (es)
MX364529B (es) Nuevos ligandos del receptor de estrógeno.
PH12014501367A1 (en) Processes for making magnolol and derivatives thereof
WO2014030173A3 (en) Improved process for preparation of atazanavir bisulfate
WO2014167509A3 (en) Loxoprofen polymorphs and process for preparation of the same
MX2014012822A (es) Proceso para elaborar derivados de naftiridina.
WO2012100005A3 (en) Synthetic transtaganolide and basiliolide products, derivatives thereof, and synthesis methods thereof

Legal Events

Date Code Title Description
FG Grant or registration